DXB: Late-stage kidney disease pipeline with global deals and strong IP drives diversified growth
Two late-stage assets target high unmet needs in kidney disease: DMX-200 for FSGS is in Phase 3 with global licensing deals valued up to AU$1.9 billion, while DMX-652 for AKI is Phase 2 ready with a unique mitophagy mechanism. Strong IP, diversified revenue, and experienced leadership underpin grow…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.